---
document_datetime: 2024-06-06 13:06:24
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rizmoic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: rizmoic-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.5957137
conversion_datetime: 2025-12-18 11:13:05.481354
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Rizmoic

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0025               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)    | 04/06/2024                          |                                             | PL                               |           |
| IAIN/0024/G          | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release | 11/01/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0023      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                     | 14/09/2023 | 03/11/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rizmoic in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Amendments to annexes I, II and III were made to implement changes in line with the SmPC guideline and the current QRD template. Removal of black triangle sign from the annexes following five years of authorisation. |
| N/0022      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                            | 08/06/2023 | 03/11/2023 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IAIN/0021/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                   | 08/03/2023 | 03/11/2023 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of the MAH                                                                                                                                                                                                                                |            |            |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| N/0020              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                         | 22/12/2022 | 03/11/2023 | PL                                |
| IG/1553             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                               | 06/12/2022 | n/a        |                                   |
| PSUSA/10753 /202203 | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                | 27/10/2022 | n/a        | PRAC Recommendation - maintenance |
| IB/0017             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                            | 05/07/2022 | n/a        |                                   |
| N/0016              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                         | 22/12/2021 | 03/11/2023 |                                   |
| PSUSA/10753 /202103 | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                | 28/10/2021 | n/a        | PRAC Recommendation - maintenance |
| IAIN/0014/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 20/05/2021 | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10753 /202009   | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                                                                                                            | 09/04/2021   | n/a        |                                  | PRAC Recommendation -   | maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------|---------------|
| IG/1359               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                        | 10/03/2021   | n/a        |                                  |                         |               |
| IA/0012               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                        | 15/12/2020   | 01/02/2021 | SmPC, Annex II, Labelling and PL |                         |               |
| PSUSA/10753 /202003   | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                                                                                                            | 29/10/2020   | n/a        |                                  | PRAC Recommendation     | - maintenance |
| IB/0009               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                        | 13/08/2020   | n/a        |                                  |                         |               |
| PSUSA/10753 /201909   | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                                                                                                            | 17/04/2020   | n/a        |                                  | PRAC Recommendation     | - maintenance |
| IAIN/0008/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging | 23/03/2020   | 01/02/2021 | Annex II and PL                  |                         |               |

<div style=\"page-break-after: always\"></div>

|           | manufacturing site for the FP - Primary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |     |                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------|
| IAIN/0007 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/03/2020 | n/a |                              |
| II/0005/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.z - Change in the manufacturing process of product - Other variation                                                                                                                                                                                                                                                                                                                                                                         | 05/03/2020 | n/a | the finished or intermediate |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                   |            |            |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004             | Update of section 5.2 of the SmPC based on the final report from non-clinical study S-297995-PF-360-N submitted as agreed in the letter of recommendation to CHMP: In-vitro data determining whether naldemedine inhibits in a time dependent manner the OATP1B1, OATP1B3, OAT1 and OAT3 transporters. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 30/01/2020 | 01/02/2021 | SmPC                | Results of in vitro study S-297995-PF-360-N did not demonstrate significant inhibitory effect of S-297995 monotosylate on the in vitro transporter activity of OATP1B1, OATP1B3, OAT1, or OAT3 in the tested concentrations (max concentration=10 μmol/L). There¬fore, Naldemedine administered in the attended amount of 200 µg is not expected to affect the pharmacokinetics of co-administered drugs that are substrates of these transporters. |
| PSUSA/10753 /201903 | Periodic Safety Update EU Single assessment - naldemedine                                                                                                                                                                                                                                                                                                                                                                                            | 17/10/2019 | 16/12/2019 | SmPC and PL         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10753/201903.                                                                                                                                                                                                                                                                                                          |
| IA/0003             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                         | 12/07/2019 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0001/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                   | 13/06/2019 | 16/12/2019 | SmPC, Labelling and |                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|